11.01.17
NattoPharma has debuted MenaQ7 Full Spectrum K2. This latest innovation is the result of a proprietary technological breakthrough, creating a vitamin K2 that provides menaquinones (MK) 6, 7, 8, and 9, a range of isomers vital for cardiovascular health.
“NattoPharma has driven the creation of the vitamin K2 market, sponsoring the important research validating the importance of K2 for human health, and this work has shaped the MenaQ7 brand,” said NattoPharma Chief Medical Officer Dr. Hogne Vik. “The epidemiological studies that led us to our ground-breaking human clinical research used fermented cheese as the source of vitamin K2, which led us to create MenaQ7 Full Spectrum.”
According to researchers closely linked to these epidemiological studies: “Vitamin K is a fat-soluble vitamin that plays an unequivocal role in the activation of Gla-proteins. Although all K-vitamins have the same function, they differ in bioavailability and bioactivity. The Rotterdam and Prospect studies have shown that food-derived vitamin K (such as from cheeses) improves long-term cardiovascular health outcomes because it more specifically delivers the long-chain menaquinones MK-6, 7, 8, and 9.”
“While fermented cheeses are the best dietary source of menaquinones in the West, most will not be able to consume enough to obtain optimal amounts of vitamin K2, nor is cheese a practical source for extracting the menaquinones,” added Dr. Vik. “To that end, NattoPharma has once again broken the mold and offers to the market a raw material that delivers the range of menaquinones found in foods.”
The first and only vitamin K2 to deliver a gamut of menaquinone isomers, MenaQ7 Full Spectrum is naturally fermented using chickpea protein, offering an all-trans vitamin K2 that is free from gluten, soy and all known allergens, and is suitable for vegans and vegetarians. MenaQ7 Full Spectrum provides the vital menaquinone isomers MK-6, 7, 8, and 9 for optimal and maximal delivery of vitamin K2 with respect to absorption, half-life and biological activity.
“NattoPharma has driven the creation of the vitamin K2 market, sponsoring the important research validating the importance of K2 for human health, and this work has shaped the MenaQ7 brand,” said NattoPharma Chief Medical Officer Dr. Hogne Vik. “The epidemiological studies that led us to our ground-breaking human clinical research used fermented cheese as the source of vitamin K2, which led us to create MenaQ7 Full Spectrum.”
According to researchers closely linked to these epidemiological studies: “Vitamin K is a fat-soluble vitamin that plays an unequivocal role in the activation of Gla-proteins. Although all K-vitamins have the same function, they differ in bioavailability and bioactivity. The Rotterdam and Prospect studies have shown that food-derived vitamin K (such as from cheeses) improves long-term cardiovascular health outcomes because it more specifically delivers the long-chain menaquinones MK-6, 7, 8, and 9.”
“While fermented cheeses are the best dietary source of menaquinones in the West, most will not be able to consume enough to obtain optimal amounts of vitamin K2, nor is cheese a practical source for extracting the menaquinones,” added Dr. Vik. “To that end, NattoPharma has once again broken the mold and offers to the market a raw material that delivers the range of menaquinones found in foods.”
The first and only vitamin K2 to deliver a gamut of menaquinone isomers, MenaQ7 Full Spectrum is naturally fermented using chickpea protein, offering an all-trans vitamin K2 that is free from gluten, soy and all known allergens, and is suitable for vegans and vegetarians. MenaQ7 Full Spectrum provides the vital menaquinone isomers MK-6, 7, 8, and 9 for optimal and maximal delivery of vitamin K2 with respect to absorption, half-life and biological activity.
